Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
Biological (large molecule) drug products are made via living systems and are complex and variable in nature. As a result, generic forms of biological products, also termed biosimilars in the EU or follow-on biologics by the US Food and Drug Administration, can only be similar to the reference product, unlike generic versions of small molecule drug products that contain the exact same active ingredient as the brand-name drug. Compared with small molecule drug products, more stringent assessment of safety, purity, and potency is needed to show that a follow-on biologic is not clinically different from the reference biological product. This paper addresses statistical criteria for establishing biosimilarity and interchangeability of follow-on biologics as set forth by the Biologics Price Competition and Innovation Act. It also highlights the scientific issues regarding the assessment of follow-on biologics that are currently still unresolved within the US.
Authors and Affiliations
Shein-Chung Chow, Christine Ju
Keywords
Related Articles
- EP ID EP355086
- DOI 10.5639/gabij.2013.0201.004
- Views 103
- Downloads 0
Latest features in GaBI Journal, 2013, Issue 3
The GaBI Journal again contains manuscripts covering a wide range of pertinent topics. In an Editorial, Dr Gianluigi Casadei reviews Italy’s final position paper on biosimilars including the new price and reimbursement p...
The case for biosimilars–a payer’s perspective
Biosimilars have the potential for making savings in healthcare costs, and with resource allocation, if competition is permitted at the level of treatment induction.
The potential of generics policies: more room for exploitation–PPRI Conference Report
Introduction: This Conference Report aims to provide an overview of key results, messages and conclusions of the Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference with regard to generics. Methods: Th...
Efficient production of recombinant parathyroid hormone (rPTH) fragment 1-34 in the methylotrophic yeast Hansenula polymorpha
Background: Osteoporosis is a bone disease of the elderly that leads to increased risk of fracture. Currently, it affects more than 200 million adults worldwide, placing an enormous economic burden on healthcare provider...
Biosimilar monoclonal antibodies approved for use in the EU
Two biosimilar TNF-alfa monoclonal antibody (mAb) products were approved for clinical use in the European Union on 10 September 2013, following a positive opinion by the Committee for Medicinal Products for Human Use (CH...